JSM 2021 Online Program
Return to main conference page
Online Program Home
My Program
All Times EDT
Legend:
* = applied session ! = JSM meeting theme
Activity Details
Tweet
29
Sun, 8/8/2021, 1:30 PM - 3:20 PM
Virtual
Statistical Issues Specific to Therapeutic Areas, Power and Sample Size Calculations, and Trial Monitoring — Contributed Speed
Biopharmaceutical Section
Chair(s): Jonathan Moscovici, QuintilesIMS
1:35 PM
A Bayesian Network Meta-Analysis on Treatments of Brain Metastases in Patients with Non-Small Cell Lung Cancer
Uma Siangphoe, Johnson and Johnson
1:40 PM
On Characterizing Survival Curve of CAR-T Cell Therapy
1:45 PM
On Treatment Effect in Sequential Parallel Comparison Design
1:50 PM
WITHDRAWN: Comparison of Methods for Adjusting for Crossover in Oncology Trials
1:55 PM
Handling Multiple Imputation in Wilcoxon Signed-Rank Test: A Case Study Applied to a Hemophilia Clinical Trial
2:00 PM
An Alternate Method to Find the Confidence Interval for the Difference Between Two Proportions of Rare Event
2:05 PM
A Flexible Ensemble Learning Method for Survival Extrapolation
2:10 PM
Methods for Vaccine Efficacy in a Fixed Duration Design with Censoring
2:15 PM
Novel Measures of Treatment Efficacy Under Delayed Treatment Effects
2:20 PM
Sample Size Reestimation for the Finkelstein and Schoenfeld Test Statistic for a Composite Endpoint with Two Components
2:30 PM
Power Analyses of Oncology Clinical Trials with Stratified Randomization
2:35 PM
Something Out of Nothing? The Influence of 0-0 Studies in Bayesian Meta-Analysis of Drug Safety Studies
2:40 PM
Incorporating Historical Controls in Analyses of Clinical Trial Data: An Empirical Power Prior Approach
2:45 PM
Do unadjusted pilot analyses lead to biased decision in proceeding to a larger trial?
2:50 PM
Optimizing Precision and Power in COVID-19 Trials by Covariate Adjustment
2:55 PM
Collaborative Biostatistics as a Bridge from Preclinical Discovery to Population Data Science
3:00 PM
Interim Analysis Incorporating Intermediate Binary Responses
3:05 PM
Predicting Analysis Times in Clinical Trials with Nonproportional Hazards
3:10 PM
Realistic Patient-Level Simulators Considering Two Dependent Time-to-Event Endpoints
3:15 PM
Floor Discussion
↑
